Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Apolizumab"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Brian K. Link, John P. Leonard
Publikováno v:
Seminars in oncology. 29(1S2)
Clinical activity of anti-CD20 monoclonal antibodies both in the unlabeled (rituximab [Rituxan; Genentech, Inc, South San Francisco, CA, and IDEC Pharmaceuticals, San Diego, CA]) and radiolabeled forms, as well as radioimmunoconjugates targeting othe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::465dd9f5286bbf5ce5142db6fa3714f9
https://pubmed.ncbi.nlm.nih.gov/28140096
https://pubmed.ncbi.nlm.nih.gov/28140096
Autor:
Tadeusz Robak
Publikováno v:
Acta Haematologica Polonica. 43:99-106
STRESZCZENIE Przeciwciala monoklonalne przyczynily sie do znacznego postepu w leczeniu przewleklej bialaczki limfocytowej (CLL). Najwieksze znaczenie kliniczne mają obecnie alemtuzumab i rytuksymab. Rytuksymab jest hybrydowym ludzkim/mysim przeciwci
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6c133bc20d6b46288cf7c5dd4fcbbbf3
https://doi.org/10.1016/s0001-5814(12)32003-3
https://doi.org/10.1016/s0001-5814(12)32003-3
Autor:
Susan O'Brien, Karen W.L. Yee
Publikováno v:
Expert Opinion on Emerging Drugs. 11:167-189
Although the philosophy of management of patients with chronic lymphocytic leukaemia (CLL) has been altered with the advent of fludarabine-based therapies, impact on long-term survival is unclear and a significant proportion of patients will develop
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::045b53dded1ed7061b498b76e2545b06
https://doi.org/10.1517/14728214.11.1.167
https://doi.org/10.1517/14728214.11.1.167
Autor:
Bruce D. Cheson, Blanche H. Mavromatis
Publikováno v:
Blood Reviews. 18:137-148
New therapies for chronic lymphocytic leukemia (CLL) are moving away from non-specific cytotoxic to more targeted approaches. The monoclonal antibody alemtuzumab induces responses in 33% to 43% of patients with relapsed or refractory disease, with 2-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::58b915018e0db54cf07435dbcba0961b
https://doi.org/10.1016/s0268-960x(03)00039-0
https://doi.org/10.1016/s0268-960x(03)00039-0
Autor:
Tadeusz Robak
Publikováno v:
Non-Hodgkin Lymphoma ISBN: 9781461458500
Over the last few years, several new monoclonal antibodies (mAbs) directed against lymphoid cells have been developed and investigated in indolent non-Hodgkin lymphoma (NHL). New generations of anti-CD20 mAbs were engineered to have augmented antit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::24435a46737851dd742f9d34dae46824
https://doi.org/10.1007/978-1-4614-5851-7_11
https://doi.org/10.1007/978-1-4614-5851-7_11
Autor:
Carolyn Cheney, Wendy Stock, Huiping Xu, Mitch A. Phelps, Bruce R. Briggs, Sara K. Guster, Thomas S. Lin, Margaret S. Lucas, John C. Byrd, Ian W. Flinn, James T. Dalton, Pierluigi Porcu, Michael R. Grever
Publikováno v:
Leuk Lymphoma
Apolizumab (Hu1D10), a humanized monoclonal anti- Human leukocyte antigen -DR beta-chain antibody, mediates apoptosis of chronic lymphocytic leukemia (CLL) cells in vitro. We conducted a phase I/II dose-escalation study of thrice-weekly apolizumab (1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de294cc29a36cc33dac195afe27556ff
https://europepmc.org/articles/PMC8166408/
https://europepmc.org/articles/PMC8166408/
Autor:
Tadeusz Robak
Publikováno v:
Current cancer drug targets. 8(2)
For many years, alkylating agents and purine nucleoside analogs (PNA) have been considered the drug of choice for treatment of chronic lymphocytic leukemia (CLL). More recently the introduction of monoclonal antibodies (mAb), especially rituximab dir
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::970a6be418dcbd92b4fd828cec9ee292
https://pubmed.ncbi.nlm.nih.gov/18336199
https://pubmed.ncbi.nlm.nih.gov/18336199
Autor:
Thomas Valerius, Juergen Rech, Bernhard Stockmeyer, Dorit Rech, Gerald Niedobitek, Michael Dechant, Martin Gramatzki, Roland Repp
Publikováno v:
Leukemialymphoma. 47(10)
Apolizumab is a humanized monoclonal antibody against a polymorphic epitope on HLA DRbeta that demonstrated evidence for therapeutic activity in follicular lymphoma patients. In pre-clinical studies, we previously reported that granulocyte colony-sti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e2ab53686bab8d3f9de2f03fa5539d39
https://pubmed.ncbi.nlm.nih.gov/17071489
https://pubmed.ncbi.nlm.nih.gov/17071489
Autor:
Kieron Dunleavy, John E. Janik, Margaret Shovlin, Therese White, M Stetler-Stevenson, Gerald E. Marti, Nicole Grant, Wyndham H. Wilson, Stefania Pittaluga, E. S. Jaffe
Publikováno v:
Journal of Clinical Oncology. 23:6607-6607
6607 Background: Apolizumab (Apo), a humanized IgG1 mAb, targets ID10, and rituximab (R), a chimeric IgG1 mAb, targets CD20, both of which are expressed on normal and malignant B-cells. These mAb’s...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::248b86084a0787ec1b323b3fba2db91b
https://doi.org/10.1200/jco.2005.23.16_suppl.6607
https://doi.org/10.1200/jco.2005.23.16_suppl.6607